You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,773,244


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,773,244
Title: Methods of making circular RNA
Abstract:A prototype RNA cyclase ribozyme that allows efficient production of circular RNA. Methods for modifying the prototype to produce a wide variety of custom circular RNA are detailed. The method utilizes a new plasmid which enables production of a wide variety of imaginable RNA sequences in a covalent, circular form free from intron sequences in vitro. At a particular site in the plasmid, a sequence coding for the desired circular RNA is inserted to create a new RNA cyclase ribozyme gene. RNA transcribed from RNA cyclase ribozyme genes autocatalytically converts the desired RNA sequence it contains into circular form. RNA cyclase genes may be placed into appropriate expression vectors for synthesis of circular RNA in vivo as part of ribozyme or antisense gene regulation approaches to genetic engineering.
Inventor(s): Ares, Jr.; Manuel (Santa Cruz, CA), Ford; Ethan E. (Harbor, NY)
Assignee: Regents of the University of California (Oakland, CA)
Application Number:08/431,896
Patent Claims:1. A method for producing a circular RNA, said method comprising the steps of:

(a) providing a target nucleic acid sequence to be made circular;

(b) making a DNA construct encoding an RNA cyclase ribozyme, wherein the arrangement of regions that code for RNA cyclase ribozyme splicing elements is an encoded 3' portion of an intron, an encoded 3' splice site, the target nucleic acid sequence of step (a), an encoded 5' splice site and an encoded 5' portion of the intron;

(c) expressing the DNA construct as an RNA; and,

(d) allowing the RNA to self-splice, thereby producing the circular RNA.

2. The method of claim 1, wherein the DNA construct is a plasmid and the target nucleic acid is inserted into an exon of the plasmid in a site of a polylinker in the exon using a procedure selected from the group of procedures consisting of cloning, the polymerase chain reaction, and oligonucleotide directed mutagenesis.

3. The method of claim 2, wherein nucleotides of the polylinker are removed from the plasmid by oligonucleotide directed mutagenesis or by deletion using restriction enzymes.

4. The method of claim 3, wherein the plasmid is expressed in vivo in cells in culture by transcription after introduction of the plasmid into the cells by transformation, viral transduction, microinjection, electroporation or liposome mediated transformation.

5. The method of claim 3, wherein the plasmid is expressed by in vitro transcription.

6. The method of claim 5, wherein the in vitro transcription comprises encoding a transcription termination site at the end of the 5' portion of the intron and by initiating RNA transcripts in the 3' portion of the intron which are transcribed to encode RNA corresponding to the 3' splice site, the target nucleic acid sequence, 5' splice site and the 5' portion of the intron.

7. The method of claim 4, wherein the RNA cyclase ribozyme splicing elements are derived from group I self-splicing introns.

8. The method of claim 7, wherein the group I self-splicing intron is bacteriophage T4 td intron.

9. The method of claim 1, wherein the circular RNA is produced either in vitro, or in vivo in cell in culture.

10. The method of claim 9, wherein the circular RNA is produced in yeast.

11. The method of claim 9, wherein the circular RNA is produced in bacteria.

12. A circular RNA of a nucleic acid sequence produced by a method comprising the steps:

(a) providing a target nucleic acid sequence to be made circular;

(b) making a DNA construct encoding an RNA cyclase ribozyme, wherein the arrangement of regions that code for RNA cyclase ribozyme splicing elements is an encoded 3' portion of an intron, an encoded 3' splice site, the target nucleic acid sequence of step (a), an encoded 5' splice site and an encoded 5' portion of the intron;

(c) expressing the DNA construct as an RNA; and,

(d) allowing the RNA to self-splice in a circular form to produce said circular RNA.

13. A method of making a repeating protein product from a circular RNA, the method comprising the steps:

(a) providing a nucleic acid sequence to be made circular;

(b) making a DNA construct encoding an RNA cyclase ribozyme, wherein the arrangement of regions that code for RNA cyclase ribozyme splicing elements is an encoded 3' portion of an intron, an encoded 3' splice site, the nucleic acid sequence of step (a), an encoded 5' splice site and an encoded 5' portion of the intron;

(c) expressing the plasmid as RNA; and

(d) allowing the RNA to selfsplice, thereby producing a circular RNA; and

(e) translating the circular RNA in an appropriate translation system, thereby producing a repeating protein product from the circular RNA.

14. A plasmid for producing a circular RNA having an arrangement of the regions that code for the splicing elements that constitute an RNA cyclase ribozyme, wherein said arrangement is a 3' portion of an encoded intron, an encoded 3' splice site, a target nucleic acid, an encoded 5' splice site and a 5' portion of the intron.

15. The plasmid of claim 14, wherein the plasmid is pEFC created by inserting the 580 bp Sph1-Xba1 fragment of pTZtd18-2 into the unique EcoR1 site of pTZtd18-1 containing the tandem lac and phage T7 promoters.

16. The plasmid of claim 14, wherein the plasmid is pEFC.DELTA.Nde created by cutting plasmid pEFC with Nde1 and ligating the large fragment back together, further containing a minimal amount of td exon sequence and a unique Nde1 site.

17. The plasmid of claim 14, wherein the plasmid is pEFC-.DELTA.NAct(+) created by inserting the 452 bp Sma1-HindIII fragment of pT7Act into the Nde1 site of pEFC.DELTA.Nde, further containing the tandem lac and T7 promoters.

18. The plasmid of claim 14, wherein the plasmid is p.DELTA.N-Y(+) created by inserting the 499 bp xbaI fragment of pEFC.DELTA.Nde into pYES.

19. The plasmid of claim 14, wherein the plasmid is p.DELTA.N-A(+)-G(+) created by inserting the 452 bp Sma1-HindIII fragment of pT7Act into p.DELTA.N-Y(+).

20. The plasmid of claim 14, wherein the plasmid is pRR1.

21. A nucleic acid encoding an RNA cyclase ribozyme with the following arrangement of elements: a 3' portion of an intron, a 3' splice site, a nucleic acid subsequence which encodes a polypeptide, a 5' splice site and a 5' portion of the intron.

22. An RNA encoded by the nucleic acid of claim 21.

23. A DNA construct encoding the nucleic acid of claim 21.

24. A cell comprising the nucleic acid of claim 21.

25. A method of making a circular RNA comprising expressing an RNA encoded by the nucleic acid of claim 21 in a cell in culture and permitting the RNA encoded by the nucleic acid to self-splice, thereby producing a circular RNA.

26. The nucleic acid of claim 21, wherein the intron is a group I intron.

Details for Patent 5,773,244

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2015-06-30
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2015-06-30
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2015-06-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.